Blueberry Therapeutics reels in USD 12.7 Million in series B funding for fungal infections.
U.K.based, Blueberry Therapeutics successfully bagged a funding of USD 12.7 million in series B funding. The funding will help the company to advance its nanomedicine candidate, BB2603 for two fungal infections namely- Athlete’s foot and fungal nail infections. BB2603 is a nanoformulated form of terbinafine, which is an antifungal treatment, it is currently in the phase 2 and is expected to enter the phase 3 soon after the funding.
Pfizer remunerates Germany’s BioNTech $120M for forming mRNA flu vaccine agreement.
Pfizer reimburses a $425 million deal for working with BioNTech to produce mRNA influenza vaccines. To get into R&D association, the Big Pharma, Pfizer is providing $120 million beforehand and near-term payments.
In mRNA field, BioNTech spearheads that heads to deals with Sanofi, Eli Lilly andGenentech and a $270 million series A.
Orchard has grabbed USD 150 Million in Series C funding for multifront late-phase gene therapy.
Orchard Therapeutics has snatched a whooping sum of USD 150 Million in Series C funding round to proceed three gene therapies towards approval. Orchard has maintained the transformative steak started in the first half of this year with GSK gene therapies acquisition, including the less used approved drug, Strimvelis. The funding will help in the growth and development of the expanded company pipeline.
Artios Pharma secured USD 84 Million for clinical trials of next generation DNA damage response drugs .
U.K. based pharmaceutical company, Artios Pharma has recently bagged USD 84 Million for accelerating its DNA damage response (DDR) programs in clinical trails. Artios Pharma entered into the DDR programs after in-licensing it from Cancer Research Technology in 2016.